Shares of GlaxoSmithKline plc (LON:GSK) have earned an average recommendation of “Hold” from the twenty-six analysts that are covering the stock. Three analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is GBX 1,679.82 ($20.79).
A number of research analysts recently weighed in on the company. Credit Suisse Group AG reiterated a “neutral” rating and issued a GBX 1,800 ($22.28) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 14th. S&P Global Inc. set a GBX 1,650 ($20.42) price objective on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Wednesday, July 27th. Beaufort Securities restated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, June 21st. BNP Paribas restated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. Finally, Citigroup Inc. set a GBX 1,800 ($22.28) price objective on GlaxoSmithKline plc and gave the stock a “buy” rating in a research note on Thursday, September 29th.
GlaxoSmithKline plc (LON:GSK) opened at 1700.00 on Tuesday. The company’s 50-day moving average price is GBX 1,649.81 and its 200-day moving average price is GBX 1,561.10. The stock’s market cap is GBX 82.64 billion. GlaxoSmithKline plc has a 1-year low of GBX 1,277.25 and a 1-year high of GBX 1,745.56.
The company also recently declared a dividend, which was paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th were paid a dividend of GBX 19 ($0.24) per share. This represents a yield of 1.12%. The ex-dividend date was Thursday, August 11th.
In other news, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.95), for a total transaction of £169,300 ($209,529.70). Also, insider Slaoui,Moncef acquired 28 shares of GlaxoSmithKline plc stock in a transaction dated Friday, August 12th. The shares were bought at an average cost of GBX 2,208 ($27.33) per share, with a total value of £618.24 ($765.15).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.